Merck and Ridgeback initiate Covid-19 trial of oral antiviral therapeutic
Merck and Ridgeback Biotherapeutics have initiated a Phase III clinical trial to evaluate investigational oral antiviral therapeutic molnupiravir to prevent Covid-19 infection.